Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Levkovitz, Y., Sheer, A., Harel, E. V., Katz, L. N., Most, D., Zangen, A., & Isserles, M. (2011). Brain stimulation, 4(4), 266-274.
This study examined the effect of the Brainsway® Deep TMS (Transcranial Magnetic Stimulation) H-coil stimulation on depressed patients, and evaluated separately the effect on depressive symptoms and on one of depression’s core symptoms – apathy. In the study, antidepressant medication treatment was ceased, and Deep Transcranial Magnetic stimulation was given 5 days a week, over 4 weeks. The study demonstrated that brain stimulation using the Deep TMS H-coil significantly alleviates depressive symptoms including apathy, but only if pre-treatment apathy was not very severe.